[Inflammatory bowel disease--the role and issue of glucocorticoid].
We herein reviewed the clinical applications of glucocorticoid (GC) hormones to inflammatory bowel disease (IBD). In the therapeutic strategy for active ulcerative colitis, topical/systemic GC administration is still central during these fifty years. However, non -responders to GC are present at 30-40% of the active UC patients. We analyzed the expression of GC receptor isoform, namely hGRbeta, in peripheral blood mononuclear cells, and suggest the possibility that expression of hGRbeta, induced by proinflammatory cytokine IL-18, is closely related GC resistance in UC.
Ashida
Toshifumi
T
Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical College.
D003093:Colitis, Ulcerative / Q000188:drug therapy; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D011965:Receptors, Glucocorticoid / Q000032:analysis
D005938:Glucocorticoids; D011965:Receptors, Glucocorticoid